- Home
- ALXO vs PHUN Comparison
ALXO vs PHUN Comparison
Compare ALXO & PHUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | PHUN |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 55.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | PHUN |
|---|---|---|
| Price | $1.46 | $2.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.30 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 274.6K | 161.1K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $73.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $1.83 |
| 52 Week High | $2.27 | $6.29 |
Technical Indicators
Market Signals| Indicator | ALXO | PHUN |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 43.36 |
| Support Level | $1.29 | $2.01 |
| Resistance Level | $1.60 | $2.16 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 73.75 | 72.22 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.